Posts

Posted on

Inaugural “LiveXLive Presents The Lockdown Awards” Will Be Hosted By GRAMMY Award® Nominee Trey Songz

LiveXLive’s Show Will Stream on December 11, 2020 Honoring Artists and Entertainers Who Create Content for Fans Amidst COVID-19 with Over 4 Billion in Social Media Reach

PRESENTERS INCLUDE MEG DONNELLY, BUSTA RHYMES, INFINITY SONG, KIIARA, ALEX ROSE, TIGIRLILY, and MORE

LAUV AND CONAN GRAY ADDED TO PERFORM

PR Newswire

LOS ANGELES, Dec. 2, 2020/PRNewswire/ — LiveXLive Media (NASDAQ:LIVX) (“LiveXLive”), a global platform for livestream and on-demand audio, video and podcast content in music, comedy, and pop culture, owner of content in music, comedy and pop culture, and owner of PodcastOne, Slacker Radio and React Presents announced today the host and presenters of LiveXLive’s “The Lockdown Awards”. Hosting the event is award winning singer, songwriter and actor Trey Songz. Presenters will include Puerto Rican Urban Star Alex Rose,Hip Hop luminary Busta Rhymes, sibling band and music collectiveInfinity Song, singer-songwriter Kiiara, singer/songwriter Meg Donnelly, and Pop-country duo Tigirlily.

INAUGURAL “LIVEXLIVE PRESENTS THE LOCKDOWN AWARDS” WILL BE HOSTED BY GRAMMY AWARD® NOMINEE TREY SONGZ

With a global audience from around the world, the evening will be filled with performances by: Ally Brooke, Avenue Beat, Icona Pop & Sofi Tukker and Wiz Khalifa. Just added will be a special performance of their hit ‘Fake’ by Lauv and Conan Gray. The show reflects the ingenuity and creativity artists have put forth to keep connecting with fans worldwide.


Nominations are in the following 15 categories:


A Quarantine Ditty: Favorite Quarantine Song, All the Feels: Favorite Song for the Soul, Digital Chemistry: Favorite Duet, Musicians Not Playing Music

,

I Heart that Song: Favorite Cover

,

Mind = Blown: Favorite Use of Tech, No Stage, No Problem: Favorite Outdoor Performance, Room with a View: Favorite Creative Direction

,

Sights & Sounds: Most Like a Music Video, Stronger Together: Favorite Group / All-Star Performance

,

The Best Fest: Favorite Virtual Festival, The New New: Favorite New Music Series, The Room Where It Happens: Favorite Home Performance, Way-Off Broadway: Favorite Musical Reunion

,

Zoom Tune: Zoom Performance.

This outstanding group of nominees represents over 4 billion in social media reach.

“Bringing artists and fans together in meaningful ways is a priority for LiveXLive. We believe that celebrating the unprecedented efforts of artists under a singularly unique award show, reflecting the diverse creative digital landscape, will make for a celebration like none-other. Trey Songz and the amazing performances and presenters are going to make for an unforgettable event,” stated Garret English, Chief Content Officer of LiveXLive.

LiveXLive has become a go-to platform for live streaming events that combine music with pop culture of podcasting, sports, arts, fashion, culinary and comedy. From emerging to established artists, LiveXLive has streamed a variety of artists and celebrities in 2020 alone: Kygo, Jimmy Buffett, OneRepublic, Zac Brown Band, Sofi Tukker, Graham Parker, John Hiatt, John Butler, Michael Franti, Nahko, Trevor Hall, FINK, Mike Love, Rising Appalachia, Krishna Das, Big Gigantic, Hot Chelle Rae, Lauren Jauregui, Billy Joel, Bon Jovi, Chris Rock, Idina Menzel, Jennifer Lopez, Sullivan King, Quix, Nitti Gritti, Dr. Fresch, Champagne Drip, and Pegboard Nerds. So far in calendar year 2020, LiveXLive has streamed over 1,500 artists and content has been viewed over 95 million times.



About Trey Songz



Home means many different things. For as much as it represents a physical place, it really embodies our personal roots, defining who we become and, ultimately, what we do. Beginning with his Atlantic Records debut I Gotta Make It in 2005, singer, actor, philanthropist, entrepreneur, and performer Trey Songz has built an essential discography speaking his own truth. Beyond earning just shy of 8 billion global streams and sales combined and garnering three GRAMMY® Award nominations to date, he has notched 16-plus RIAA Certified platinum and gold singles and albums. Plus, he has logged two consecutive #1 debuts on the Billboard Top 200 with the RIAA gold-certified Chapter V in 2012 and RIAA platinum-certified TRIGGA in 2014. Most recently, 2017’s RIAA gold-certified Tremaine captured #3 on the Top 200. 

In 2020, he brought the next chapter of his career to life with the release of his 8

th

studio album, BACK HOME. Brightened by the captivating records “



Two Ways



,” “



Circles



,” “



2020 Riots: How Many Times



” and “



Back Home (Feat. Summer Walker)



,” BACK HOME was met by widespread critical acclaim and impressive feats. The Hitmaka-helmed nostalgic title track “Back Home” [feat. Summer Walker] catapulted to #7 on Billboard Adult R&B Airplay Chart as his biggest R&B radio hit since 2014. On the other end of the spectrum, the powerful and politically charged “2020 Riots: How Many Times” addressed the unrest in society and turbulent tides. As chronicled on tape in the music video, Trey personally took to the streets by hosting his own Black Lives Matter Weekend Event in Petersburg and Richmond, VA to celebrate JuneTeenth 2020. As if that weren’t enough, Trey tapped fellow stars Summer Walker, Ty Dolla $ign, Swae Lee and Davido for guest spots on the album, putting the finishing touches on what has become a pristine body of work. Billboard summed up the album best, “The Virginia crooner floats back to his 2005 I Gotta Make It days, and whips up a sweet medley of sturdy deep-cut type tracks.”
Along with critical acclaim, upon its release, BACK HOME reached major feats, debuting at #1 on Billboard’s R&B Albums Chart and breaking the Top 10 on Billboard’s R&B/Hip-Hop Albums Chart. 



About LiveXLive Media, Inc.



Headquartered in Los Angeles, California, LiveXLive Media, Inc. (NASDAQ: LIVX) (the “Company”) (pronounced Live “by” Live) is a global platform for live stream and on-demand audio, video and podcast content in music, comedy, and pop culture. LiveXLive, which has streamed over 1,500 artists since January 2020, has become a go-to partner for the world’s top artists and celebrity voices as well as music festivals concerts, including Rock in Rio, EDC Las Vegas, and many others. In April 2020, LiveXLive produced its first 48-hour music festival called “Music Lives” with tremendous success as it earned over 50 million views and over 5 billion views for #musiclives on TikTok on 100+ performances. LiveXLive’s library of global events, video-audio podcasts and original shows are also available on Amazon, Apple TV, Roku and Samsung TVs in addition to its own app, destination site and social channels. The Company’s wholly-owned subsidiary, PodcastOne,
generates more than 2.1 billion downloads annually across more than 300 podcasts.
For more information, visit www.livexlive.com and follow us on Facebook, Instagram, TikTok, Twitter at @livexlive.



Forward-Looking Statements



All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including: the Company’s reliance on one key customer for a substantial percentage of its revenue; the Company’s ability to consummate any proposed financing or acquisition and the timing of the closing of such proposed transactions, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of any proposed transaction will not occur; the Company’s ability to continue as a going concern; the Company’s ability to attract, maintain and increase the number of its users and paid subscribers; the Company identifying, acquiring, securing and developing content; the Company’s ability to maintain compliance with certain financial and other covenants; the Company successfully implementing its growth strategy, including relating to its technology platforms and applications; management’s relationships with industry stakeholders; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; risks and uncertainties applicable to the businesses of the Company’s subsidiaries; and other risks, uncertainties and factors including, but not limited to, those described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 26, 2020, Quarterly Report on Form 10-Q for the quarter ended September June 30, 2020, filed with the SEC on November 16, 2020, and in the Company’s other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements, except as may be required by law. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.



Press Contact:



The Rose Group


[email protected]

 




[email protected]





424-645-4620



LiveXLive IR Contact:




[email protected]


310 – 601-2500

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inaugural-livexlive-presents-the-lockdown-awards-will-be-hosted-by-grammy-award-nominee-trey-songz-301183758.html

SOURCE LiveXLive Media, Inc.

Posted on

Ampio’s Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress

PR Newswire

ENGLEWOOD, Colo., Dec. 2, 2020 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that its AP-014 Phase I inhaled Ampion™ clinical study in COVID-19 patients is proceeding to full open enrollment following clearance by the Safety Monitoring Committee (SMC), which found Ampion to be safe and well-tolerated after reviewing results from the first three treatment groups. The trial can now accelerate to complete enrollment of the remaining 34 patients at the speed of recruitment.

“The primary goal of this trial is to confirm the safety of inhaled Ampion, so we are pleased the SMC found no concerns after treatment of the first sets of patients,” Michael Macaluso, President and CEO of Ampio Pharmaceuticals. “The enrollment of patients will proceed quickly, perhaps doubling the number of patients enrolled by the end of today.

“We were also encouraged,” continued Macaluso, “by a letter we received from staff at the hospital, sharing the dramatic improvement seen in a patient after using nebulized Ampion. Full confirmation of Ampion’s efficacy awaits the conclusion of our clinical trial, but it is heartening to hear good news when it comes to COVID-19.”

In the trial, Ampion is administered to patients by inhalation, allowing the drug to directly target and attenuate inflammation in the lungs, using a hand-held nebulizer for COVID-19 patients early in the disease and non-invasive ventilation (face mask) and mechanical ventilation (intubation) if their disease state is more severe.

This trial, being conducted in the United States, will enroll 40 patients, randomized 1 to 1, inhaled Ampion versus Standard of Care (SOC), with each patient inhaling 8 ml doses of Ampion four (4) times a day for five (5) days. Safety is the primary end point, and various measurements indicative of efficacy are secondary endpoints. Since inhalation is a new method for the administration of Ampion, cleared for clinical use by the FDA, each of the first three patient groups receiving inhaled Ampion were assessed by the SMC for an additional three days after the five-day treatment period. No safety concerns arose in any of these groups, and, as such, the trial was approved to complete full enrollment.

In related news, the Journal of Translational Medicine this week published a peer-reviewed paper on the method of action of Ampion, entitled “LMWF5A suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC,” by G. Thomas, et al. The research provides evidence that Ampion, a low molecular weight fraction of human serum albumin (LMWF5A), reduces pro–inflammatory cytokine release by activating the immunoregulatory transcription factors PPARγ and AhR while also suppressing NF–κB and STAT1α pro–inflammatory pathways.

“This paper, in a high-impact journal, confirms that Ampion reduces inflammation through multiple pathways, unlike many other anti-inflammatory therapies that target only one,” concluded Macaluso. “Inflammation is one of the body’s most important survival mechanisms, so suppressing only one pathway merely forces the body to activate other pathways. Ampion targets multiple pathways simultaneously to interrupt the destructive cycle of inflammation and disease observed in many different inflammatory conditions.”

About Ampio Pharmaceutical
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of Ampion, our product candidate, to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio’s lead drug, Ampion, is backed by an extensive patent portfolio with intellectual property protection extending through 2032 and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (BPCIA).

Forward Looking Statements
Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations with respect to the safety and efficacy of Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biologics License Application (BLA), the ability of Ampio to enter into partnering or licensing arrangements, current or future clinical trials, changes in business conditions and similar events (including currently unforeseen risks associated with COVID-19), the possibility that Ampion may be used to treat ARDS induced by COVID-19, Ampio’s ability to continue as a going concern and its ability to continue to raise funds using its “at-the-market” equity offering or otherwise, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, in Ampio’s Annual Report on Form 10-K for the period ended December 31, 2019, and in subsequent reports on Forms 10-Q and 8-K and other filings made by Ampio with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on these forward-looking statements. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact
Investor Relations
Joe Hassett
[email protected]
484-686-6600

Media Relations
Sarah May
[email protected]
215-205-1217

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ampios-phase-i-study-for-inhaled-ampion-advances-to-completing-enrollment-of-covid-19-patients-with-respiratory-distress-301183745.html

SOURCE Ampio Pharmaceuticals, Inc.

Posted on

Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List

Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List

DUBLIN–(BUSINESS WIRE)–
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has been named to Great Place to Work’s 2020 Best Workplaces for Parents list, which highlights companies that have created consistently positive experiences for working parents, especially in light of the COVID-19 pandemic.

“Horizon is honored to receive this recognition during what has been an unprecedented and difficult year for working parents and caregivers,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “As a father, I understand the unique challenges that parents face. Both in ‘normal’ times and during the pandemic, our goal is always to offer best-in-class benefits and create progressive programming that supports employees at each phase of their life.”

To aid parents and caregivers throughout the COVID-19 pandemic, Horizon launched an internal virtual community, providing free educational content, tips and ideas for working remotely with children at home. Additionally, the company announced Little Horizons, an onsite childcare center set to open January 2021 on Horizon’s Deerfield, Ill. campus for the children of Horizon employees. In response to employee-parent needs during the pandemic, the center will also house the Horizon Study Club, which will provide in-center supervision for school-age children of Horizon employees who are attending school virtually.

Horizon has a suite of benefits to support working parents. The company provides 10 weeks of paid time off for all birth and adoptive parents, regardless of gender, during parental leave; offers up to $10,000 in adoption support and gives a Care@Work membership to each employee, providing access to a caregiver database and free back-up care support. Horizon also offers a scholarship fund that provides 25 awards for children of Horizon employees for post-high school education and a Make It Personal account, where employees receive up to $500 to use toward childcare or tutoring expenses.

Great Place to Work determined the Best Workplaces for Parents list by gathering and analyzing confidential employee experience feedback from U.S. employees across more than 20 industries – the largest annual study of working parents to date. In addition to the Best Workplaces for Parents list, Horizon also ranked as one of the “Best Medium Workplaces,” “Best Workplaces in Chicago” and “Best Workplaces in Health Care and Biopharma” by Great Place to Work and FORTUNE this year.

About Horizon

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

About the Best Workplaces for Parents list

Great Place to Work based its ranking on a data-driven methodology applied to confidential Trust Index™ survey responses representing over 4.8 million employees working at Great Place to Work-Certified™ organizations. To learn more about Great Place to Work Certification and recognition on Best Workplaces lists published with Fortune, visit greatplacetowork.com.

About Great Place to Work

Great Place to Work® is the global authority on workplace culture. They help organizations quantify their culture and produce better business results by creating a high-trust work experience for all employees. They recognize Great Place to Work-Certified™ companies and the Best Workplaces™ in the U.S. Learn more at greatplacetowork.com and on LinkedIn, Twitter and Instagram.

U.S. Media Contacts:

Geoff Curtis

Executive Vice President, Corporate Affairs & Chief Communications Officer

[email protected]

Ireland Media Contact:

Gordon MRM

Ray Gordon

[email protected]

KEYWORDS: Illinois Europe Ireland United States North America

INDUSTRY KEYWORDS: Biotechnology Professional Services Other Health Health Philanthropy Pharmaceutical Other Philanthropy Consumer Science Human Resources Parenting

MEDIA:

Logo
Logo
Posted on

PharmaCyte Biotech Successfully Completes 9-Month Stability Study

PharmaCyte Biotech Successfully Completes 9-Month Stability Study

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration (FDA) for its CypCaps™ final product, which will be used in the company’s planned clinical trial in locally advanced, inoperable pancreatic cancer.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said of the completed nine-month stability study, “The product stability studies of our CypCaps™ product initiated prior to submitting our Investigational New Drug application (IND) to the FDA are still proceeding smoothly while we are answering the questions raised by the FDA following our IND submission. We are also starting additional studies designed to provide information that the FDA has requested, which are mainly focused on the handling of the CypCaps™ product in the clinic, and on additional animal data to add to the data that we have already supplied in our IND package.

“The ongoing stability study is designed to determine the shelf life of the Cell-in-a-Box® encapsulated cell product, CypCaps™, frozen at -80°C, and I am pleased to report that the nine-month time point was recently reached and that CypCaps™ passed all of the necessary tests, including cell viability, enzyme activity and cell potency, pH, label check, capsule appearance and integrity. This nine-month data, as well as all future longer-term time points of the shelf life analyses, such as the next milestone, the 12-month time point, will be reported to the FDA as an update to our submitted IND.”

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company’s documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and we believe results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human liver cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is also considering the use of genetically modified stem cells to treat diabetes. The encapsulation of the cell lines will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to raise the necessary capital to fund our operations and to find partners to supplement our capabilities and resources, our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

Dr. Gerald W. Crabtree

Investor Relations:

PharmaCyte Biotech, Inc.

Investor Relations Department

Telephone: 917.595.2856

Email: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: FDA Diabetes Clinical Trials Stem Cells Other Health Biotechnology General Health Pharmaceutical Health Oncology

MEDIA:

Logo
Logo
Posted on

A88CBD™ Now Offered by KeHE

A88CBD™ Now Offered by KeHE

  •  KeHE, a leading national natural food distributor, services 12,000 customers with access to over 30,000 stores

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–
The Alkaline Water Company Inc. (NASDAQ and CSE: WTER) (the “Company”) is a producer of premium bottled alkaline water, flavor-infused waters, and CBD infused products sold under the brand names Alkaline88®, A88 Infused™, and A88CBD™, respectively. Today, the Company announces an expanded partnership with KeHE, which now includes the A88CBD™ topical products, A88 Infused™ flavors, and the entire Alkaline88® line, including eco-friendly aluminum bottles.

“KeHE has been an exceptional partner in our journey to become a national lifestyle brand,” stated Ricky Wright, President and CEO of The Alkaline Water Company. “We are excited to announce that our premium quality, lab-tested A88CBD topical products will now be available to all KeHE accounts nationwide. Today, our flagship brand, Alkaline88, is being offered by thousands of KeHE customers, and the distributor has quickly become a top account for the Company. This large and growing partner has been a key contributor to our five-year reported growth CAGR of over 60%. And over the last three years, we have done approximately $25 million in retail sales with their customers.”

“As a trusted brand, our beverage offerings have seen steady growth across a majority of their accounts, and more recently, we have seen a pickup in orders for our single-serve offerings, including our eco-friendly aluminum bottles and our A88 Infused flavored waters. With an increasing consumer appetite for CBD infused products, we expect our growing line of all-natural A88CBD topical and eventually our ingestible offerings to see strong growth at this leading national specialty and all-natural food distributor. We look forward to an expanding and rewarding relationship with KeHE in the coming years.”

About KeHE

KeHE Distributors, LLC is a Specialty & Natural and Organic & Fresh food distributor in the U.S. and Canada. KeHE’s U.S. Distribution customers include chain grocery, chain natural, independent grocery, and independent natural retailers. Total revenue is approximately $5.5 billion. For more about KeHE, visitKeHE.com.

The Alkaline Water Company

Founded in 2012, The Alkaline Water Company (NASDAQ and CSE: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts our trademarked label ‘Clean Beverage.’ Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the Company launched A88 Infused Beverage Division Inc., which includes the Company’s CBD water and flavor-infused water. For the Company’s topical and ingestible offerings, A88 Infused Products Inc. includes both the Company’s lab-tested full-spectrum hemp salves, balms, lotions, essential oils, and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules, and gummies.

To purchase A88CBD™ products online, visit us at www.A88CBD.com. To learn more about The Alkaline Water Company, please visit www.thealkalinewaterco.com or connect with us on Facebook, Twitter, Instagram, or LinkedIn.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements.” Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the following: the Company’s journey to become a national lifestyle brand; that the Company expects its growing line of all-natural A88CBD topical and eventually its ingestible offerings to see strong growth at this leading national specialty and all-natural food distributor; that the Company looks forward to an expanding and rewarding relationship with KeHE in the coming years.

The material assumptions supporting these forward-looking statements include, among others, that the demand for the Company’s products will continue to significantly grow; that the past production capacity of the Company’s co-packing facilities can be maintained or increased; that there will be increased production capacity through implementation of new production facilities, new co-packers and new technology; that there will be an increase in number of products available for sale to retailers and consumers; that there will be an expansion in geographical areas by national retailers carrying the Company’s products; that there will be an expansion into new national and regional grocery retailers; that there will be an expansion into new e-commerce, home delivery, convenience, and healthy food channels; that there will not be interruptions on production of the Company’s products; that there will not be a recall of products due to unintended contamination or other adverse events relating to the Company’s products; and that the Company will be able to obtain additional capital to meet the Company’s growing demand and satisfy the capital expenditure requirements needed to increase production and support sales activity. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, governmental regulations being implemented regarding the production and sale of alkaline water or any other products, including products containing hemp/CBD; the fact that consumers may not embrace and purchase any of the Company’s CBD-infused products; the fact that the Company may not be permitted by the FDA or other regulatory authority to market or sell any of its CBD-infused products; additional competitors selling alkaline water and enhanced water products in bulk containers reducing the Company’s sales; the fact that the Company does not own or operate any of its production facilities and that co-packers may not renew current agreements and/or not satisfy increased production quotas; the fact that the Company has a limited number of suppliers of its unique bulk bottles; the potential for supply-chain interruption due to factors beyond the Company’s control; the fact that there may be a recall of products due to unintended contamination; the inherent uncertainties associated with operating as an early stage company; changes in customer demand and the fact that consumers may not embrace enhanced water products as expected or at all; the extent to which the Company is successful in gaining new long-term relationships with new retailers and retaining existing relationships with retailers; the Company’s ability to raise the additional funding that it will need to continue to pursue its business, planned capital expansion and sales activity; and competition in the industry in which the Company operates and market conditions. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States and Canada. Although the Company believes that any beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Readers should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents the Company files with the SEC, available at www.sec.gov, and on the SEDAR, available at www.sedar.com.

The Alkaline Water Company Inc.

Richard A. Wright

President and CEO, or

Sajid Daudi

Director of Investor Relations & Corporate Communications

800-923-1910

[email protected]

Media

Jessica Starman

888-461-2233

[email protected]

KEYWORDS: Arizona United States North America

INDUSTRY KEYWORDS: Other Consumer Supermarket Specialty Alternative Medicine Food/Beverage Health Consumer Retail Online Retail

MEDIA:

Logo
Logo
Posted on

Keto Holdings Joins Draganfly Reseller Program

Innovative healthcare consulting company to implement
Smart Vital Sign technology

Los Angeles, CA., Dec. 02, 2020 (GLOBE NEWSWIRE) — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, is pleased to announce that Keto Holdings, LLC (“Keto”) has joined the Draganfly reseller program and is taking initial delivery of Smart Vital technology assessment units.

Keto provides healthcare-based consulting services to multiple industries including pharmaceutical, food processing, nursing home and travel. Keto is working with several high-profile clients to roll out Draganfly’s Vital Intelligence platform.

Draganfly’s Vital Intelligence assessment station and screening technology is quick and non-invasive (contactless). The stations can automatically detect elevated body temperature and, with voluntary consent, heart rate, respiratory rate and O2 saturation, all from a camera that takes seconds to capture the information. Draganfly’s Vital Intelligence platform has several delivery capabilities including an API for 3rd party developers to integrate the technology with their own apps and devices.

“We are looking forward to ensuring that the industries which we serve have the latest technology to help assess potential cases of Covid-19,” said Brett Louderback, Founder and Executive Director of Keto. “Draganfly’s commitment to providing the most up to date, secure and accurate vital signs screening available makes them the ideal solution for our customer base.”

 “We are incredibly excited to be providing Keto the latest in our Smart Vital Sign technology which they will implement across the multiple industries they work with,” said Cameron Chell, CEO of Draganfly.

The Company also announces that it has completed an initial closing of its previously announced Regulation A+ offering (the “Offering”) of units of the Company (“Units”). The Company issued 2,556,496 Units at price of US$0.47 per Unit for gross proceeds in the amount of US$1,201,553 in ‎this first closing. Each Unit is comprised of one common share of the Company (“Common Share”) and one Common Share purchase warrant (“Warrant”), with each Warrant entitling the holder to acquire one Common Share at a price of US$0.71 per Common Share until November 30, 2022. The Common Shares and Warrants issued in connection with the Offering are subject to a nine month hold period which will expire on August 30, 2021.

About Draganfly

Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge and software and systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer and technology developer serving the public safety, agriculture, industrial inspections, security, and mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives.

For more information on Draganfly, please visit us at www.draganfly.com.
For additional investor information, visit https://www.thecse.com/en/listings/technology/draganfly-inc, https://www.otcmarkets.com/stock/DFLYF/overview or https://www.boerse-frankfurt.de/aktie/draganfly-inc.

Media Contact
Arian Hopkins
email: [email protected]

Company Contact
Email: [email protected]

Forward-Looking Statements

This news release contains certain “forward looking statements” and certain “forward-looking ‎‎‎‎information” ‎as defined under applicable Canadian securities laws. Forward-looking statements ‎‎‎‎and information can ‎generally be identified by the use of forward-looking terminology such as ‎‎‎‎‎“may”, “will”, “expect”, “intend”, ‎‎“estimate”, “anticipate”, “believe”, “continue”, “plans” or similar ‎‎‎‎terminology. Forward-looking statements ‎and information are based on forecasts of future ‎‎‎‎results, estimates of amounts not yet determinable and ‎assumptions that, while believed by ‎‎‎‎management to be reasonable, are inherently subject to significant ‎business, economic and ‎‎‎‎competitive uncertainties and contingencies. Forward-looking statements ‎include, but are not ‎‎‎‎limited to, statements with respect the ‎successful use of the Vital Intelligence technology‎. Forward-‎‎‎looking statements ‎and information are ‎subject to various known and unknown risks and ‎‎‎uncertainties, many of ‎which are beyond the ability of ‎the Company to control or predict, that ‎‎‎may cause the ‎Company’s actual results, performance or ‎achievements to be materially different ‎‎‎from those ‎expressed or implied thereby, and are developed ‎based on assumptions about such ‎‎‎risks, ‎uncertainties and other factors set out here in, including but not ‎limited to: the potential ‎‎‎impact of ‎epidemics, pandemics or other public health crises, including the ‎current outbreak of ‎‎‎the novel ‎coronavirus known as COVID-19 on the Company’s business, operations ‎and financial ‎‎‎condition, ‎the successful integration of technology, the inherent risks involved in the ‎general ‎‎‎securities ‎markets; uncertainties relating to the availability and costs of financing needed in the ‎‎‎‎future; the ‎inherent uncertainty of cost estimates and the potential for unexpected costs and ‎‎‎expenses, ‎‎currency fluctuations; regulatory restrictions, liability, competition, loss of key ‎‎‎employees and ‎other ‎related risks and uncertainties disclosed under the heading “Risk Factors“ ‎‎‎in the Company’s ‎most recent ‎filings filed with securities regulators in Canada on the SEDAR ‎‎‎website at ‎www.sedar.com. The Company ‎undertakes no obligation to update forward-looking ‎‎‎information ‎except as required by applicable law. ‎Such forward-looking information represents ‎‎‎‎managements’ best judgment based on information ‎currently available. No forward-looking ‎‎‎‎statement can be guaranteed and actual future results may vary ‎materially. Accordingly, readers ‎‎‎‎are advised not to place undue reliance on forward-looking statements ‎or information.‎



Posted on

Stericycle Divests Its Global Product Recall Business

BANNOCKBURN, Ill., Dec. 02, 2020 (GLOBE NEWSWIRE) — Stericycle, Inc. (Nasdaq: SRCL) today announced that it has completed the divestiture of its global product recall business (Expert Solutions) to Sedgwick. Stericycle intends to use the net proceeds from the divestiture to pay down outstanding debt.

“The sale of Expert Solutions demonstrates our continued commitment to deliver on our key business priorities,” said Cindy J. Miller, Chief Executive Officer of Stericycle. “By streamlining Stericycle to its core businesses, we are able to focus greater attention on driving quality of revenue initiatives and improving sustainable operational efficiencies throughout our business.”

“I would like to thank our team members transitioning to Sedgwick. We are confident that Sedgwick will ensure continued quality of service for customers,” Miller added.

The divested business includes approximately 315 team members and seven facilities in the United States, United Kingdom and Canada.

BofA Securities acted as the financial advisor to Stericycle with respect to the transaction to divest the global product recall business and Polsinelli acted as legal advisor.

ABOUT STERICYCLE

Stericycle, Inc., (Nasdaq: SRCL) is a U.S. based business-to-business services company and leading provider of compliance-based solutions that protects people, promotes health and safeguards the environment.  Stericycle serves customers in the U.S. and 17 countries with solutions for regulated waste and compliance solutions, secure information destruction, and patient engagement.  For more information about Stericycle, please visit www.stericycle.com.

SAFE HARBOR STATEMENT

This press release may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995.  When we use words such as “believes,” “expects,” “anticipates,” “estimates,” “may,” “plan,” “will,” “goal” or similar expressions, we are making forward-looking statements.  Forward-looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and projections of our management about future events and are therefore subject to risks and uncertainties, which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.  Factors that could cause such differences include, among others, our proposed private offering of the Notes and the related guarantees and our use of the proceeds from such offering, developments in the COVID-19 pandemic and the resulting impact on the results of operations, precautions we have taken to safeguard the health and safety of our employees which may make certain of our business processes less efficient, measures taken by governmental authorities to prevent the spread of the COVID-19 virus which could disrupt our supply chain, result in disruptions in transportation services and restrictions on the ability of our employees to travel, result in temporary closure of our facilities or the facilities of our customers and suppliers, affect the volume of paper processed by our secure information destruction business and the revenue generated from the sale of sorted office paper (“SOP”), disruptions in our relationships with our employees as a result of certain cost-saving measures, an economic slowdown in the U.S. and other countries resulting from the outbreak of the COVID-19 virus, SOP pricing volatility, foreign exchange rate volatility in the jurisdictions in which we operate, the volume and size of any recall events, changes in governmental regulation of the collection, transportation, treatment and disposal of regulated waste or the proper handling and protection of personal and confidential information, the level of government enforcement of regulations governing regulated waste collection and treatment or the proper handling and protection of personal and confidential information, decreases in the volume of regulated wastes or personal and confidential information collected from customers, the ability to implement our enterprise resource planning (ERP) system, charges related to portfolio rationalization or the failure of divestitures to achieve the desired results, failure to consummate transactions with respect to non-core businesses, the obligations to service substantial indebtedness and comply with the covenants and restrictions contained in our credit agreements and notes, a downgrade in our credit rating resulting in an increase in interest expense, political, economic, inflationary and other risks related to our foreign operations, the outcome of pending or future litigation or investigations including with respect to the U.S.  Foreign Corrupt Practices Act, changing market conditions in the healthcare industry, competition and demand for services in the regulated waste and secure information destruction industries, failure to maintain an effective system of internal control over financial reporting, delays or failures in implementing remediation efforts with respect to existing or future material weaknesses, disruptions in or attacks on information technology systems, as well as other factors described in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and subsequent Quarterly Reports on Forms 10-Q.  As a result, past financial performance should not be considered a reliable indicator of future performance, and investors should not use historical trends to anticipate future results or trends.  We disclaim any obligation to update or revise any forward-looking or other statements contained herein other than in accordance with legal and regulatory obligations.

FOR FURTHER INFORMATION CONTACT:
Stericycle Investor Relations 847-607-2012

 



Posted on

Muscle Maker Grill Delivering 2nd Miami Florida Location

Fast casual company signs agreement to expand its delivery only ghost kitchen presence in Miami

League City, Texas, Dec. 02, 2020 (GLOBE NEWSWIRE) — Muscle Maker, Inc. (Nasdaq: GRIL) the parent company of Muscle Maker Grill, Healthy Joe’s and MMG Burger Bar, a fast casual concept known for serving “healthier for you” meals, today announced it has signed an agreement to open its 11th delivery only ghost kitchen in Miami’s Wynwood neighborhood. This will be the company’s second south Florida ghost kitchen location in addition to the new state of the art food court which is outfitted with a kiosk for guests to order directly currently being built out in Miami Beach. The company expects the Miami Beach location to open first quarter of 2021 and the Wynwood location will open shortly thereafter.

Similar to Miami Beach, the Wynwood neighborhood in Miami attracts forward-thinking health trends with its cultural and entertainment-focused vibe. Wynwood is known for its art galleries, restaurants, breweries, clothing stores, dance venues, and murals that cover the walls of many buildings, attracting a younger demographic to work and live in the area. This ghost kitchen location will service area residents with Healthy Joes, Muscle Maker Grill and Meal Plan AF through third party delivery apps.

“The Wynwood location will be a great compliment to our Miami Beach location and south Florida portfolio. We will be able to service both beach side and Miami proper customers, giving us access to millions of people. Our target customer fits perfectly with what the Wynwood neighborhood has to offer and we believe our brands will do very well. We are excited to add the second Miami location to our growing portfolio of ghost kitchens in Chicago, Philadelphia, San Francisco, Sacramento, Providence and NYC markets” said Michael Roper, CEO of Muscle Maker Grill.

About Muscle Maker Grill

Founded in 1995 in Colonia, New Jersey, Muscle Maker Grill features high quality, great tasting food, freshly prepared with proprietary recipes. The menu, created with the guest’s health in mind, is lean and protein based. It features all-natural chicken, grass fed steak, lean turkey, whole wheat pasta, wraps, bowls and more. It also offers a wide selection of fruit smoothies in a variety of assorted flavors, protein shakes and supplements. For more information on Muscle Maker Grill, visit www.musclemakergrill.com.

Forward-Looking Statements

This press release may include “forward-looking statements” pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. To the extent that the information presented in this press release discusses financial projections, information, or expectations about our business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as “should”, “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in documents that we file from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Muscle Maker, Inc does not undertake any duty to update any forward-looking statements except as may be required by law.

Contact:

Muscle Maker Grill Marketing
[email protected]

Investor Relations:
[email protected]



Posted on

Spok Rated as #1 Secure Healthcare Provider Communications Platform for the Fourth Consecutive Year

Spok Rated as #1 Secure Healthcare Provider Communications Platform for the Fourth Consecutive Year

Voted top-rated secure communications platform by healthcare clients in Black Book Research survey as health systems face an increase in cybersecurity attacks

SPRINGFIELD, Va.–(BUSINESS WIRE)–Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK) and a global leader in healthcare communications, earned top honors for the fourth consecutive year in a survey of healthcare industry clients by Black Book Research on top-rated secure communications platforms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201202005008/en/

“The honor means more this year than ever, and demonstrates our market leadership, as healthcare systems continue to battle COVID-19,” said Vincent D. Kelly, president and chief executive officer of Spok Holdings, Inc. “Since the onset of the pandemic, healthcare systems have faced an increase in data breaches and security threats. Being a top-performing cybersecurity software and service vendor is crucial.”

Kelly added, “We are honored that year after year Spok has ranked number one in this survey, proving that our customers can continue to count on us for secure and reliable care team communications, especially during these unprecedented times.”

From third to fourth quarter 2020, Black Book Research’s secure communications platform client/user survey investigated over 30 solutions vendors used by more than 1,600 validated users nationwide. Ballots from nearly 1,500 healthcare organizations were received and validated for this spotlight survey of user satisfaction and utilization trends.

Spok received the highest honors for customer satisfaction in 12 of the 18 copyrighted key performance indicators Black Book Research measures including strategic alignment with client goals, innovation, reliability, support and customer care, and best of breed technology.

For the full rankings and methodology click here.

About Spok

Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Springfield, Virginia, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Go® and Spok Care Connect® platforms to enhance workflows for clinicians and support administrative compliance. Our customers send over 100 million messages each month through their Spok® solutions. When seconds count and patients’ lives are at stake, Spok enables smarter, faster clinical communication. For more information, visit spok.com or follow @spoktweets on Twitter. 

Spok is a trademark of Spok Holdings, Inc. Spok Go and Spok Care Connect are trademarks of Spok, Inc. 

Katlyn Nesvold

+1 (952) 230-5584

[email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Software Mobile/Wireless General Health Data Management Technology Security Other Communications Public Relations/Investor Relations Communications Other Technology Telecommunications Health

MEDIA:

Logo
Logo
Photo
Photo
Posted on

BIIB INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc.

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) — Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) from October 22, 2019 through November 6, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the Central District of California alleges violations of the Securities Exchange Act of 1934.

If you purchasedBiogensecurities, and/or would like to discuss your legal rights and options please visit Biogen Shareholder Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected].

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab’s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab’s effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness; (4) the data provided by the Company to the FDA’s Peripheral and Central Nervous System Drug Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On November 6, 2020, Reuters published an article entitled “U.S. FDA panel votes cannot ignore unsuccessful trial data on Biogen Alzheimer’s drug” which provided information regarding the FDA panel’s votes.

On this news, Biogen’s stock price fell $92.64 per share, or 28%, to close at $236.26 per share on November 9, 2020, the next trading day, damaging investors.

If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased Biogen securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/biogeninc-biib-shareholder-class-action-lawsuit-fraud-stock-332/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected].

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]